Altimmune (FRA:3G0) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3G0 Altimmune Inc FRA:3G0
30 GF Score
Price €2.55
GF Value €0.29
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Altimmune Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:3G0
30GF Score
Altimmune Inc FRA:3G0
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Altimmune (FRA:3G0) Overvalued in 2026?

Based on GuruFocus' analysis, Altimmune stock appears to be overvalued. The current stock price of €2.55 is trading 779.3% above its estimated GF Value™ of €0.29. GuruFocus considers Altimmune to be Significantly Overvalued.

Key valuation signals for FRA:3G0:

  • Short Ratio:
  • GF Value™: €0.29 vs. price of €2.55 (779.3% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the FRA:3G0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Altimmune Business Description

Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
30GF Score

Get the complete analysis for FRA:3G0

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€0.29
GF Value